Conference Coverage

New agent builds bone bigger, faster

Publish date: July 17, 2014

 

AT ICE/ENDO 2014

References

These phase II studies were funded by Radius Health.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Some consider denosumab standard treatment for unresectable giant cell tumor of bone
MDedge Rheumatology
Yearly monitoring does not predict fractures after bisphosphonate cessation
MDedge Rheumatology
Atypical hip fracture risk low with bisphosphonates, but be aware
MDedge Rheumatology
Nonmelanoma skin cancer linked to increased fracture risk in postmenopausal women
MDedge Rheumatology
VIDEO: Less frequent zoledronic acid is safe, retains efficacy
MDedge Rheumatology
Monitor elderly for bone loss after gastric bypass
MDedge Rheumatology
Monitor elderly for bone loss after gastric bypass
MDedge Rheumatology
Hyponatremia linked to osteoporosis, fragility fractures
MDedge Rheumatology
Meta-analysis finds limited bone loss with low-dose glucocorticoids
MDedge Rheumatology
Fractures increased with two diabetes drugs
MDedge Rheumatology